MOORESTOWN, N.J., July 24, 2017 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company optimizing medication safety by deploying new Medication Risk Mitigation digital solutions and novel Medication Decision Support tools, will release its second quarter 2017 operating results on Monday, August 7, 2017 after market close, on the investor relations section of TRHC’s website at ir.trhc.com with a conference call hosted by TRHC’s management to follow at 5:00 p.m. EDT.
Stockholders and interested participants may listen to a live broadcast of the conference call by dialing 844-413-0947 or 216-562-0423 for international callers, and referencing participant code 54995292 approximately 15 minutes prior to the call. A live webcast of the conference call will be available on the investor relations section of TRHC’s website (ir.trhc.com) and an audio file of the call will also be archived and available for replay approximately two hours after the live event for a period of 90 days thereafter at ir.trhc.com. After the conference call, a replay will be available until August 14, 2017 and can be accessed by dialing 855-859-2056 or 404-537-3406 for international callers, and referencing participant code 54995292.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.TRHC.com.
Contact: Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected] Media Dianne Semingson [email protected] 215-870-0829


South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 



